

REMARKS**Status of the Claims**

Claims 1 and 7 are pending and are rejected. Claims 2-6 and 8-22 were canceled previously and claims 1 and 7 are canceled herein. New claims 23-27 are added. No new matter is added in any new claim.

Amendments to the claims

The Examiner has proposed allowable new claims 23-24 and 26-27 as shown above. The Examiner's originally proposed claim 23 is drawn to a method for treating prostate cancer that comprises administering to a patient having prostate cancer a conjugate comprising bismuth-213 and an antibody specific for prostate cancer cells. Claim 24 limits the specific activity of the bismuth-213 conjugate is about 20 mCi/mg or about 30 mCi/mg as recited in canceled claim 1. Claim 26 corresponds to canceled claim 7. Claim 27 limits administration of the conjugate to intravenous administration as recited in canceled claim 1.


Applicants further propose the additional recitation of the species actinium-225 as shown in claim 23 supra. As such, Applicants have added "bismuth-213" to the Examiner's claim 24 and also propose claim 25 which corresponds to claim 24, but recites that the specific activity of the actinium-225 conjugate is about 0.0012 mCi/mg or about 0.12 mCi/mg (see Example 18).

Applicants submit that claims 23-27, as presented herein, are in condition for allowance. Accordingly, Applicants request that claims 23-27 be passed to

issuance. If any issues remain, the Examiner is respectfully requested to telephone the undersigned attorney for immediate resolution.

Respectfully submitted,

Date: Dec 4, 2008
ADLER & ASSOCIATES
8011 Candle Lane
Houston, Texas 77071
Tel.: (713) 270-5391
Fax: (713) 270-5361
Ben@adlerandassociates.com


Benjamin Aaron Adler, Ph.D., J.D.
Registration No. 35,423
Counsel for Applicant